STUDY QUESTION Can the luteal phase support be improved in terms of efficacy, hormonal profiles and convenience as compared with today's standard care? SUMMARY ANSWER Daily low-dose rhCG supplementation in GnRHa triggered IVF cycles can replace the traditional used luteal phase support with exogenous progesterone. WHAT IS KNOWN ALREADY A bolus of hCG for final maturation of follicles in con...

Background Follicle cryopreservation has been proposed as an alternative fertility preservation option. Follicles can be cryopreserved in intact ovarian tissue pieces or after isolation of individual follicles from the fresh ovarian tissue using enzymatic or mechanical techniques. Researchers have used different cryoprotectants and various techniques to improve cryopreservation. It is plausible...

Background Since the success rate in older poor-responder (POR) infertile women is expected to be extremely low irrespective of the treatment protocol, clinicians continue the search for biomarkers which may predict cases in which proceeding with follicle aspiration may be appropriate. Experimental studies on murine model suggest that SCF(Stem- Cell-Factor) produced by ovarian cumulus granulosa...

Background The hypothesis that the LDA (low-dose-aspirin) could improve ovarian and uterine perfusion induced clinicians to administer it in women undergoing IVF. Unfortunately, no studies have shown significant differences in terms of pregnancy rate among patients treated or untreated with LDA. The absence of proven clinical benefits of LDA supplementation, led us to wonder whether aspirin, ad...

Background Current strategies based on random selection of MII-oocytes to fertilize appear unsatisfactory in selecting the best number and the most vital oocytes to fertilize especially in poor responder women in which “chronological age” does not mismatch with “biological age”. The metabolomics- profiling approach, evaluating the final products of cell regulatory process (genome/transcriptome/...

It has been 35 years since Professor Thoenes and his colleagues discovered chromophobe renal cell carcinoma (RCC). Since then, our knowledge about this tumour entity changed novel entities have discovered. The aim of review is to discuss recent molecular findings open questions in diagnosing chromophobe-like/oncocytic neoplasms. broader differential diagnosis chromophobe-like oncocytoma-like ne...